Cargando…
Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines
In recent years, adoptive cell therapy has gained a new perspective of application due to the development of technologies and the successful clinical use of CAR-T cells for the treatment of patients with malignant B-cell neoplasms. However, the efficacy of CAR-T therapy against solid tumor remains a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953664/ https://www.ncbi.nlm.nih.gov/pubmed/36831162 http://dx.doi.org/10.3390/biomedicines11020626 |
_version_ | 1784893934167654400 |
---|---|
author | Valiullina, Aigul Kh. Zmievskaya, Ekaterina A. Ganeeva, Irina A. Zhuravleva, Margarita N. Garanina, Ekaterina E. Rizvanov, Albert A. Petukhov, Alexey V. Bulatov, Emil R. |
author_facet | Valiullina, Aigul Kh. Zmievskaya, Ekaterina A. Ganeeva, Irina A. Zhuravleva, Margarita N. Garanina, Ekaterina E. Rizvanov, Albert A. Petukhov, Alexey V. Bulatov, Emil R. |
author_sort | Valiullina, Aigul Kh. |
collection | PubMed |
description | In recent years, adoptive cell therapy has gained a new perspective of application due to the development of technologies and the successful clinical use of CAR-T cells for the treatment of patients with malignant B-cell neoplasms. However, the efficacy of CAR-T therapy against solid tumor remains a major scientific and clinical challenge. In this work, we evaluated the cytotoxicity of 2nd generation CAR-T cells against modified solid tumors cell lines—lung adenocarcinoma cell line H522, prostate carcinoma PC-3M, breast carcinoma MDA-MB-231, and epidermoid carcinoma A431 cell lines transduced with lentiviruses encoding red fluorescent protein Katushka2S and the CD19 antigen. A correlation was demonstrated between an increase in the secretion of proinflammatory cytokines and a decrease in the confluence of tumor cells’ monolayer. The proposed approach can potentially be applied to preliminarily assess CAR-T cell efficacy for the treatment of solid tumors and estimate the risks of developing cytokine release syndrome. |
format | Online Article Text |
id | pubmed-9953664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99536642023-02-25 Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines Valiullina, Aigul Kh. Zmievskaya, Ekaterina A. Ganeeva, Irina A. Zhuravleva, Margarita N. Garanina, Ekaterina E. Rizvanov, Albert A. Petukhov, Alexey V. Bulatov, Emil R. Biomedicines Article In recent years, adoptive cell therapy has gained a new perspective of application due to the development of technologies and the successful clinical use of CAR-T cells for the treatment of patients with malignant B-cell neoplasms. However, the efficacy of CAR-T therapy against solid tumor remains a major scientific and clinical challenge. In this work, we evaluated the cytotoxicity of 2nd generation CAR-T cells against modified solid tumors cell lines—lung adenocarcinoma cell line H522, prostate carcinoma PC-3M, breast carcinoma MDA-MB-231, and epidermoid carcinoma A431 cell lines transduced with lentiviruses encoding red fluorescent protein Katushka2S and the CD19 antigen. A correlation was demonstrated between an increase in the secretion of proinflammatory cytokines and a decrease in the confluence of tumor cells’ monolayer. The proposed approach can potentially be applied to preliminarily assess CAR-T cell efficacy for the treatment of solid tumors and estimate the risks of developing cytokine release syndrome. MDPI 2023-02-19 /pmc/articles/PMC9953664/ /pubmed/36831162 http://dx.doi.org/10.3390/biomedicines11020626 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Valiullina, Aigul Kh. Zmievskaya, Ekaterina A. Ganeeva, Irina A. Zhuravleva, Margarita N. Garanina, Ekaterina E. Rizvanov, Albert A. Petukhov, Alexey V. Bulatov, Emil R. Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines |
title | Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines |
title_full | Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines |
title_fullStr | Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines |
title_full_unstemmed | Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines |
title_short | Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines |
title_sort | evaluation of car-t cells’ cytotoxicity against modified solid tumor cell lines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953664/ https://www.ncbi.nlm.nih.gov/pubmed/36831162 http://dx.doi.org/10.3390/biomedicines11020626 |
work_keys_str_mv | AT valiullinaaigulkh evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT zmievskayaekaterinaa evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT ganeevairinaa evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT zhuravlevamargaritan evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT garaninaekaterinae evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT rizvanovalberta evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT petukhovalexeyv evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines AT bulatovemilr evaluationofcartcellscytotoxicityagainstmodifiedsolidtumorcelllines |